Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

4.306 -0.084 (-1.92%)
Streaming Delayed Price Updated: 10:10 AM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
30 31 Next >
Compass Pathways: Q1 Earnings Insights
 
Via Benzinga
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Earnings Preview: Compass Pathways
 
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
Another piece of the regulatory puzzle fell into place, but there are plenty more. 
Via The Motley Fool
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following Tuesday's approval of a joint application submitted by MAPS PBC and COMPASS... 
Via Benzinga
American Medical Association to Issue First New Code for Psychedelic Therapies
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved 
From COMPASS Pathways
Via GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
 
Via Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
Atai's stock is hurting, but its pipeline is still packed with promising programs. 
Via The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
 
Via Benzinga
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the... 
Via Benzinga
Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder
Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published... 
Via Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
 
Via Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 11, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
 
Via Benzinga
10 Short Squeeze Candidates: Getty Images Tops List, PaxMedica Rejoins Top Five, MicroStrategy Moves Up And More
Potential short squeeze plays gained steam in 2021 and continued through 2023 with new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits... 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
 
Via Benzinga
Compass Pathways, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 4, 2023
 
Via Benzinga
Compass Pathways Plc (NASDAQ: CMPS) Highlighted for Surprising Price Action
Via Investor Brand Network
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
 
Via Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.